[Antihypertensive therapy and heart diseases]

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Research

Context:

• Hypertensive heart disease, including cardiac hypertrophy and ischemic conditions, poses significant cardiovascular risks.
• Antihypertensive therapy aims to prevent and manage these complications, with regression of cardiac hypertrophy being a key goal.
• Impaired nitric oxide (NO) release in coronary arteries is a characteristic of hypertension.

Purpose:

• To evaluate the efficacy of antihypertensive agents in managing hypertensive heart disease.
• To assess the role of Angiotensin-Converting Enzyme inhibitors (ACEI) in regressing cardiac hypertrophy.
• To investigate the impact of antihypertensive drugs on coronary microvascular function and NO bioavailability.

Summary:

• ACE inhibitors demonstrate potent effects in regressing cardiac hypertrophy, thereby reducing cardiovascular event risk.
• Both ACE inhibitors and calcium channel blockers improve coronary flow reserve, particularly in microvascular circulation.
• Clinical evidence, such as the "TREND" study, supports ACE inhibitors' ability to restore reduced nitric oxide release in hypertensive patients.
• ACE inhibitors are effective for heart failure, with calcium antagonists and beta-blockers also showing positive outcomes.

Impact:

• Effective management of hypertensive heart disease through targeted pharmacotherapy can significantly lower morbidity and mortality.
• Understanding the mechanisms by which antihypertensives improve cardiac function aids in personalized treatment strategies.
• The findings support the use of ACE inhibitors as a cornerstone therapy for hypertensive cardiovascular complications.